NCT02955251 - A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 18, 2016

Primary Completion Date

October 29, 2019

Study Completion Date

October 29, 2019

Conditions

Advanced Solid Tumors Cancer

Interventions

DRUG

ABBV-428

ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.

DRUG

Nivolumab

Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.

Trial Locations (15)

2050

Chris O'Brien Lifehouse /ID# 163131, Camperdown

2065

Northern Cancer Institute /ID# 163132, St Leonards

10002

National Taiwan Univ Hosp /ID# 169034, Taipei City

13385

Hopital de la Timone /ID# 162256, Marseille

19111

Fox Chase Cancer Center /ID# 170665, Philadelphia

29605

Greenville Hospital System /ID# 154437, Greenville

33000

Institut Bergonie /ID# 202391, Bordeaux

69373

Centre Leon Berard /ID# 168072, Lyon

75248

Institut Curie /ID# 162258, Paris

78229

South Texas Accelerated Research Therapeutics /ID# 154442, San Antonio

94805

Gustave Roussy /ID# 162257, Villejuif

95817

UC Davis Comprehensive Cancer Center - Main /ID# 154439, Sacramento

85258-2345

HonorHealth Research Institute - Pima /ID# 155461, Scottsdale

60637-1443

University of Chicago /ID# 154440, Chicago

77030-4000

MD Anderson Cancer Center at Texas Medical Center /ID# 154441, Houston